+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 42 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating tabelecleucel, an allogeneic T-cell immunotherapy, for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease EBV PTLD in patients after failure of rituximab or rituximab plus chemotherapy. This phase 3, multicenter, open-label trial focuses on participants who have undergone solid organ transplant or allogeneic hematopoietic cell transplant and whose disease has not responded to prior standard treatments. Participants receive intravenous tabelecleucel in 5-week cycles, with doses given on Days 1, 8, and 15 of each cycle, followed by observation through Day 35. Treatment continues until the participant achieves a maximal response, experiences unacceptable side effects, starts other therapies, or fails the tabelecleucel treatment. The study includes different cohorts based on transplant type and prior therapies, and all participants have confirmed availability of partially HLA-matched tabelecleucel. Throughout the study, participants undergo assessments including PET-CT or MRI scans to evaluate disease status, with additional brain imaging if central nervous system involvement exists. Researchers monitor response rates, duration of response, overall survival, and safety events such as allograft loss or rejection over a follow-up period of up to five years. Participants are observed closely to understand the benefits and risks of tabelecleucel in this condition.

All AgesAll GendersPhase 3
71 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of azenosertib ZN-c3, an oral selective WEE1 inhibitor, in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors express Cyclin E1 protein, identified through a specialized assay. The study includes multiple parts, with Part 2 specifically enrolling Cyclin E1 positive patients to better understand the drugs impact in this subgroup. Participants receive azenosertib orally, following an intermittent dosing schedule of 400 mg once daily for 5 days, then 2 days off. Different dosing arms exist, including a 300 mg dose, all administered under careful monitoring. The study is randomized and open-label, with several parts completed and Part 2c actively enrolling. The treatment period and follow-up extend for up to approximately 12 months to assess various outcomes. During the study, participants undergo tumor testing, disease evaluation by standard imaging criteria RECIST v1.1, and monitoring of blood markers such as CA-125. Researchers track response rates, duration of response, progression-free survival, clinical benefit, and adverse events. Regular assessments ensure safety and treatment adherence. The total participation duration encompasses treatment and follow-up phases, with outcomes measured up to about one year after the last participant enrolls.

Age: 18Years +FEMALEPhase 2
89 locations
H

Actively Recruiting

Researchers are studying HER3-DXd monotherapy in adults with locally advanced unresectable or metastatic solid tumors that have not responded to prior treatments. This proof-of-concept phase 2 trial includes participants with various cancers such as melanoma, head and neck squamous cell carcinoma, HER2-negative gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, lung cancer, and breast cancer. The study aims to assess how well HER3-DXd works and its safety in these cancers, also exploring the relationship between HER3 protein levels in tumors and treatment response. Participants will receive an intravenous infusion of HER3-DXd at a dose of 5.6 mgkg every three weeks. Treatment continues until disease progression, unacceptable side effects, or withdrawal. The study involves multiple cohorts, each with specific tumor types, and includes monitoring of drug levels in the blood, safety evaluations, and assessments of tumor response over approximately 27 months. During the trial, participants will undergo regular clinical evaluations, imaging scans such as CT or MRI to measure tumor lesions, and laboratory tests. Investigators will assess objective response rates, progression-free survival, overall survival, and treatment-emergent adverse events. Prostate cancer participants will have additional monitoring of prostate-specific antigen PSA levels. The study includes pharmacokinetic analyses of HER3-DXd and long-term follow-up to evaluate treatment effects and safety throughout the participation period.

Age: 18Years +All GendersPhase 2
96 locations
E

Actively Recruiting

Researchers are evaluating how well JNJ-101556143 works in people with metastatic androgen pathway modulation-resistant prostate cancer mAPMR, a form of advanced prostate cancer that no longer responds to hormone therapy. This study aims to measure the overall response, including tumor shrinkage or disappearance, after treatment with this investigational drug. The trial is a Phase 2, open-label, multicenter, single-arm study sponsored by Janssen Research & Development, LLC. Participants will receive JNJ-101556143 orally once daily in 28-day treatment cycles. Treatment continues until the disease shows confirmed progression by imaging or clear clinical signs, or if other protocol-defined reasons require stopping. The study evaluates the drugs effects over up to 2 years and 8 months, including response duration, progression-free survival, and time to symptom progression. During the trial, participants will undergo regular assessments including imaging scans, laboratory tests, and measurements of drug levels in the blood to monitor response and safety. Researchers will track adverse events and clinical lab abnormalities throughout. The primary outcome is the overall response rate measured over nearly three years. Participants remain on study until progression or discontinuation criteria are met, with ongoing safety and disease monitoring throughout their participation.

Age: 18Years +MALEPhase 2
14 locations
R

Actively Recruiting

Researchers are evaluating treatments for participants with metastatic colorectal cancer mCRC who have previously received irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab. The study aims to compare overall survival when using precemtabart tocentecan Precem-TcT alone, Precem-TcT combined with bevacizumab, and trifluridinetipiracil FTD-TPI plus bevacizumab. This Phase 3 trial addresses the unmet need for effective treatment options in this patient group. Participants will be randomly assigned to one of three groups Precem-TcT alone given intravenously every 3 weeks on Day 1 of each 21-day cycle Precem-TcT combined with bevacizumab administered intravenously every 3 weeks or every 2 weeks depending on the cycle or FTD-TPI tablets taken orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle along with bevacizumab. The study evaluates these treatments over cycles lasting up to an average of 19 months. During the study, participants will undergo various assessments including survival monitoring, disease progression checks, response evaluations using RECIST criteria, adverse event tracking, and quality of life questionnaires. Blood samples will be collected at specific times to measure drug concentrations and immune response markers. Researchers will assess physical functioning and health status repeatedly until treatment ends, with safety and treatment effects monitored throughout the trial period.

Age: 18Years +All GendersPhase 3
92 locations
S

Actively Recruiting

Researchers are evaluating the effects of the ABC Bicuspid Sizing Algorithm on patients with bicuspid aortic stenosis undergoing transcatheter aortic valve replacement TAVR using the Sapien 3 valve. This international, multi-center study aims to determine if the algorithm improves technical success immediately after the procedure and device success 30 days later. The study also examines how additional imaging techniques like gated computed tomography and artificial intelligence-based simulations influence treatment decisions. The study involves about 290 patients eligible for TAVR or surgical aortic valve replacement SAVR. Physicians use the ABC Bicuspid Sizing Algorithm to guide treatment allocation between TAVR and SAVR, as well as valve sizing and deployment for those receiving TAVR. Some patients may have further evaluation with gated CT or AI simulations to assess risks. Data for TAVR patients is collected at baseline, during the procedure, at hospital discharge, 30 days after, and annually up to 5 years. SAVR patients have data collected at baseline and during the procedure only. Participants will undergo diagnostic imaging including CT scans evaluated with the sizing algorithm and may receive additional assessments if indicated. Researchers collect data on procedure success, device outcomes, conduction disturbances, pacemaker implants, stroke, vascular complications, mortality, valve function, and hospitalizations for heart failure over 5 years. Follow-up visits occur at 30 days and annually, allowing long-term monitoring of outcomes after treatment.

All AgesAll Genders
20 locations
E

Actively Recruiting

Researchers are evaluating the safety and tolerability of valemetostat combined with darolutamide in adult males with Metastatic Castration Resistant Prostate Cancer mCRPC. This phase 1 trial aims to understand how these treatments work together in participants who have evidence of disease progression and metastatic spread, while continuing androgen deprivation therapy. The study is sponsored by Daiichi Sankyo and focuses on participants who have prior therapy with androgen receptor pathway inhibitors. Participants will receive valemetostat at escalating doses alongside a standard dose of darolutamide. The trial includes a dose escalation part where dosing is carefully increased, followed by a dose expansion part with two or more dose levels of valemetostat combined with darolutamide. Treatment cycles last 28 days, with valemetostat dosing monitored closely during the initial cycle and repeated in subsequent cycles. Participants will undergo assessments from screening through up to approximately 5 years, including monitoring for dose-limiting toxicities, treatment-emergent adverse events, and prostate-specific antigen PSA responses. Additional evaluations include radiographic progression, overall survival, and time to symptomatic skeletal events. Blood samples will be collected to measure plasma concentrations of the study drugs. Safety and efficacy will be closely tracked throughout the study duration.

Age: 18Years +MALEPhase 1
29 locations
S

Actively Recruiting

This research aims to evaluate the safety and effectiveness of Mirvetuximab Soravtansine in female participants aged 18 years and older who have platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high levels of folate receptor alpha FR. The study includes two groups a randomized Phase 2 group and a hepatic impairment group, with about 110 participants expected worldwide. The purpose is to better understand how this investigational antibody drug conjugate works by targeting cancer cells carrying FR to deliver a cell-killing drug. Participants in the randomized Phase 2 group receive Mirvetuximab Soravtansine intravenously on one of two schedules either a standard dose on day 1 every 21 days or a lower dose on days 1 and 15 every 28 days. The hepatic impairment group evaluates the starting dose for participants with moderately abnormal liver function, receiving different doses on day 1 of a 21-day cycle. Treatment and monitoring continue for up to about 24 months, including dose optimization and safety assessments. During the study, participants will visit the hospital or clinic regularly for medical exams, blood tests, and scans to track treatment effects and side effects. Researchers will measure responses including corneal adverse events, tumor response rates, drug concentrations in the body, and survival outcomes. Safety is closely monitored through assessments of vital signs, laboratory values, and physical exams. The total participation time is approximately 24 months, with ongoing evaluations to determine how well the treatment works and its safety profile.

Age: 18Years +FEMALEPhase 2
52 locations

1-10 of 42

1